CytoSorbents (CTSO) Q2 FY26 earnings call

CytoSorbents reported a quarter of significant operational progress, highlighted by improved gross margins and a substantial reduction in operating cash burn, positioning the company for cash flow breakeven in the second half of the year. The company also gained crucial clarity from the FDA on the regulatory pathway for DrugSorb-ATR, potentially opening the U.S. market without a new clinical trial. While core revenue remained stable, challenges in Germany and the Middle East persist, necessitating targeted sales force expansion.